Episode: 23 - Discussing Review Boards, Social Media, and World Events With Donna Dorozinsky
Description
In this episode of The Scope of Things, host Deborah Borfitz provides a rundown of the latest news in the clinical trials field: a massive health research initiative in the UK, widespread overdosing of trial participants, a cholesterol-lowering vaccine, the growing popularity of phage therapy, a novel scoring mechanism for de-risking trials for chronic diseases, a strategy for making staph vaccines a reality, and the latest oral drugs heading to trials that could eliminate one of the chief barriers to insulin therapy for diabetics. Deborah also speaks with Donna Dorozinsky, President & CEO of Just in Time GCP, about recent changes related to expectations of institutional review boards, the use of social media for recruitment and communication purposes, and the impact of world events on clinical data management.
News Roundup
Our Future Health
Medication adherence crisis
- Story covering the issues and smart packaging solutions
- PLOS One paper about overdosing of marketed drugs
Cholesterol-lowering vaccine
- Story about the bivalent vaccine and its promise
- NPJ Vaccines paper covering preclinical study results
Phage therapy
- World Economic Forum report on Top 10 Emerging Technologies of 2023
- Cell paper reviewing state-of-the-art in phage therapy
- Graham Hatfull podcast episode
Pharmagenic enrichment score
- Circulation paper on using genetics to inform interventions
- Story about how the patient scoring method enables precision medicine
Staph vaccine trials
New oral insulin drug
Guest
- D
The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.
United States
